EDIT - Editas Medicine, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
EDIT price evolution
EDIT
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $123.65 | $82.54 | $220.82 | $129.02 |
| Short term investments | $199.46 | $267.08 | $211.15 | $189.42 |
| Net receivables | $10.19 | $2.42 | $2.29 | $0.24 |
| Inventory | ||||
| Total current assets | $340.83 | $358.6 | $440.98 | $324.46 |
| Long term investments | $104.02 | $96.8 | $48.06 | $83.34 |
| Property, plant & equipment | $45.71 | $43.49 | $47.66 | $49.55 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $158.32 | $146.05 | $100.97 | $139.65 |
| Total investments | $303.48 | $363.88 | $259.22 | $272.76 |
| Total assets | $499.15 | $504.65 | $541.95 | $464.11 |
| Current liabilities | ||||
| Accounts payable | $8.27 | $10.41 | $8.07 | $9.05 |
| Deferred revenue | $68.89 | $68.89 | $68.89 | $68.89 |
| Short long term debt | $12.16 | $9.69 | $10.33 | $8.33 |
| Total current liabilities | $63.22 | $58.6 | $54.51 | $57.16 |
| Long term debt | $24.37 | $24.92 | $26.86 | $28.81 |
| Total noncurrent liabilities | $86.84 | $85.58 | $87.52 | $89.48 |
| Total debt | $36.54 | $34.61 | $37.19 | $37.14 |
| Total liabilities | $150.06 | $144.19 | $142.04 | $146.63 |
| Shareholders' equity | ||||
| Retained earnings | -$1231.35 | -$1212.48 | -$1167.46 | -$1127.17 |
| Other shareholder equity | $0.2 | -$1.45 | -$2.29 | -$2.28 |
| Total shareholder equity | $349.1 | $360.46 | $399.92 | $317.47 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $123.65 | $141.52 | $203.52 | $139.68 |
| Short term investments | $199.46 | $202.75 | $296.33 | $262.43 |
| Net receivables | $10.19 | $5.14 | $0.27 | $6.05 |
| Inventory | ||||
| Total current assets | $340.83 | $356.75 | $507.31 | $419.09 |
| Long term investments | $104.02 | $93.1 | $120.07 | $109.66 |
| Property, plant & equipment | $45.71 | $59.22 | $43.29 | $39.15 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $158.32 | $157.57 | $170.17 | $153.51 |
| Total investments | $303.48 | $295.85 | $416.4 | $372.09 |
| Total assets | $499.15 | $514.32 | $677.48 | $572.6 |
| Current liabilities | ||||
| Accounts payable | $8.27 | $9.51 | $5.05 | $6.41 |
| Deferred revenue | $68.89 | $68.89 | $72.22 | $94.93 |
| Short long term debt | $12.16 | $11.08 | $10.31 | $6.81 |
| Total current liabilities | $63.22 | $60.11 | $46.88 | $58.21 |
| Long term debt | $24.37 | $32.86 | $16.07 | $19.32 |
| Total noncurrent liabilities | $86.84 | $93.53 | $76.96 | $120.81 |
| Total debt | $36.54 | $43.95 | $26.38 | $26.14 |
| Total liabilities | $150.06 | $153.64 | $123.84 | $179.02 |
| Shareholders' equity | ||||
| Retained earnings | -$1231.35 | -$1078.13 | -$857.7 | -$665.2 |
| Other shareholder equity | $0.2 | -$3.6 | -$0.49 | -$0.05 |
| Total shareholder equity | $349.1 | $360.68 | $553.64 | $393.59 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $60.05 | $5.34 | $2.89 | $9.85 |
| Cost of revenue | ||||
| Gross Profit | $60.05 | $5.34 | $2.89 | $9.85 |
| Operating activities | ||||
| Research & development | $69.56 | $40.51 | $29.78 | $37.8 |
| Selling, general & administrative | $14.46 | $14.99 | $17.2 | $23.01 |
| Total operating expenses | $84.01 | $55.5 | $46.98 | $60.81 |
| Operating income | -$23.96 | -$50.16 | -$44.09 | -$50.96 |
| Income from continuing operations | ||||
| EBIT | -$23.98 | -$50.16 | -$44.1 | -$52.55 |
| Income tax expense | ||||
| Interest expense | -$5.1 | -$5.14 | -$3.81 | -$3.51 |
| Net income | ||||
| Net income | -$18.87 | -$45.02 | -$40.29 | -$49.04 |
| Income (for common shares) | -$18.87 | -$45.02 | -$40.29 | -$49.04 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $78.12 | $19.71 | $25.54 | $90.73 |
| Cost of revenue | ||||
| Gross Profit | $78.12 | $19.71 | $25.54 | $90.73 |
| Operating activities | ||||
| Research & development | $177.65 | $174.96 | $142.51 | $158 |
| Selling, general & administrative | $69.65 | $70.7 | $76.18 | $67.58 |
| Total operating expenses | $247.3 | $245.66 | $218.69 | $225.57 |
| Operating income | -$169.18 | -$225.95 | -$193.15 | -$134.84 |
| Income from continuing operations | ||||
| EBIT | -$170.78 | -$224.66 | -$194.84 | -$118.58 |
| Income tax expense | ||||
| Interest expense | -$17.57 | -$4.22 | -$2.34 | -$2.6 |
| Net income | ||||
| Net income | -$153.22 | -$220.43 | -$192.5 | -$115.98 |
| Income (for common shares) | -$153.22 | -$220.43 | -$192.5 | -$115.98 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$18.87 | -$45.02 | -$40.29 | -$49.04 |
| Operating activities | ||||
| Depreciation | $1.47 | $1.51 | $1.54 | $1.54 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $5.34 | $4.73 | $5.21 | $4.51 |
| Total cash flows from operations | -$22.24 | -$35.46 | -$38.71 | -$35.77 |
| Investing activities | ||||
| Capital expenditures | -$1.31 | -$0.24 | -$1.33 | -$1.84 |
| Investments | $64.15 | -$102.58 | $14.31 | $25.11 |
| Total cash flows from investing | $62.84 | -$102.82 | $12.98 | $23.27 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.51 | $117.53 | ||
| Net borrowings | ||||
| Total cash flows from financing | $0.51 | $117.53 | ||
| Effect of exchange rate | ||||
| Change in cash and equivalents | $41.11 | -$138.28 | $91.8 | -$12.5 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$153.22 | -$220.43 | -$192.5 | -$115.98 |
| Operating activities | ||||
| Depreciation | $6.06 | $6.34 | $5.05 | $3.96 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $19.8 | $29.29 | $43.4 | $23.16 |
| Total cash flows from operations | -$132.18 | -$177.35 | -$163.8 | -$179.84 |
| Investing activities | ||||
| Capital expenditures | -$4.72 | -$4.1 | -$7.98 | -$7.15 |
| Investments | $0.99 | $118.17 | -$46.49 | -$133.37 |
| Total cash flows from investing | -$3.73 | $114.07 | -$54.47 | -$140.52 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $118.04 | $1.28 | $282.11 | $224.12 |
| Net borrowings | ||||
| Total cash flows from financing | $118.04 | $1.28 | $282.11 | $224.12 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$17.87 | -$62 | $63.84 | -$96.24 |
News
Fundamentals
| Market cap | $448.90M |
|---|---|
| Enterprise value | $361.79M |
| Shares outstanding | 81.77M |
| Revenue | $78.12M |
|---|---|
| EBITDA | -$164.72M |
| EBIT | -$170.78M |
| Net Income | -$153.22M |
| Revenue Q/Q | 818.74% |
| Revenue Y/Y | 296.34% |
| P/E ratio | -2.93 |
|---|---|
| EV/Sales | 4.63 |
| EV/EBITDA | -2.20 |
| EV/EBIT | -2.12 |
| P/S ratio | 5.75 |
| P/B ratio | 1.29 |
| Book/Share | 4.27 |
| Cash/Share | 1.51 |
| EPS | -$1.87 |
|---|---|
| ROA | -30.49% |
| ROE | -42.95% |
| Debt/Equity | 0.43 |
|---|---|
| Net debt/EBITDA | -0.16 |
| Current ratio | 5.39 |
| Quick ratio | 5.39 |